Clinical Trial Update: Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed/cisplatin intercalating gefitinib for EGFR wild-type non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gefitinib (Gefitinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN